Increased sales emphasis – The goal was to de-risk, show efficacy and sell to an orthopedic company, not to grow into a standalone business. There is a limited sales team and business is generated through word of mouth or write-ups in medical journals presenting a significant opportunity for growth for a new owner. 

Repeat business – The implant has an impressive track record, but little effort has been made to build relationships with surgeons who have successfully employed it. 

Scalable Manufacturing – The current manufacturer of record possesses all necessary ISO certifications and offers the scalability required to meet market demands. 

Platform Technology – The implant’s current application is for toes but could easily be adapted to hand and other upper extremities. 

Intellectual property – The Company has valuable intellectual property for crimping of fixation for foot bone fractures and fusions. 

High success rate – The device has been in the market long enough to show that it works, is safe and effective minimizing risk for a new owner. An independent publication in a peer-review journal demonstrated a best in class fusion rates. 

Patient, surgeon satisfaction – The implant’s success rate and ease of use have won over many doctors and patients. 

Another option – The implants provide an alternative to other types of devices which have had mixed success.  It is also the revisional implant of choice when primary procedures fail. 

Partners in place – The Company has established relationships with capable outside vendors for manufacturing and logistics. It also has a complete DHF (Design History File) and QMS (Quality Management System). 

Additional complementary device – The Company is in the process of FDA clearance for a complementary device in the same space creating an additional opportunity for new owners to generate revenue. 

Cumulative Devices Implanted – Well over 2,000 

If this opportunity fits your Company, please fill out the below NDA to get started and contacted with more information.

Expansion into New Markets – There is significant potential to expand into emerging markets where the prevalence of chronic wounds is increasing in regions with aging populations. 

Technological Innovations – Continued investment in research and development can lead to the creation of more advanced and effective wound care solutions.  

Growing Market Demand – The global market for wound care devices is expanding, driven by the increasing prevalence of chronic wounds and the aging population.  

Market Focus – The Company’s device is primarily used for treating chronic and complex wounds, such as diabetic ulcers, pressure sores, venous ulcers, burn treatments and surgical wounds. 

Value Focused – The Company’s mission and values focus on patient solutions, improving quality care by fostering technology and creativity to anticipate emerging needs. 

If this opportunity fits your Company, please fill out the below NDA to get started and contacted with more information.

Revamped manufacturing – Taking production in-house would likely reduce the cost of bringing the product to market. 

Emphasizing sales – For major manufacturers in this space, there is a significant opportunity to increase penetration with existing channels. 

International business – While current sales are primarily in the U.S., there are established international customers that can be expanded with significant growth potential. 

Established brand – The product enjoys wide name recognition among medical professionals and patients for the ease and peace of mind it brings to users. 

Adaptability – It can be easily used in conjunction with other manufacturer’s medical devices. 

Lack of competition – There is no legitimate direct competitor.  

Supplier relationships – After decades of successful sales, the product is a known commodity with nearly two dozen medical supply companies.  

Our device is used with an essential complementary device 

North America –  

• Complementary device sales: 82,000,000 units annually
• Target market share: 20%
• Estimated units: 16,400,000
• Total potential revenue: $16,400,000 

International – 

• There is a significant opportunity for sales in Japan, South Korea, Australia and New Zealand as well as additional sales in Europe.
• Combined, complementary devices sales are estimated at over 100,000,000 units annually.    

2024 Revenue: $480,000 

2024 EBITDA: $250,000 

If this opportunity fits your Company, please fill out the below NDA to get started and contacted with more information.